CEPHEUS trial lead investigator Saad Z. Usmani, MD, MBA, FACP, FASCO, explains how the trial both builds on current knowledge of newly diagnosed multiple myeloma and how transplant-ineligible status ...

A renowned name in rare blood disorders research, Prof. Khaled Musallam has become the first Arab to receive the Clinical ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best stocks to buy for beginners now. On June 12, Bristol Myers Squibb ...

A compelling session at the EHA Congress explored how space research is reshaping our understanding of hematologic processes.

Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.

Experts reassess endpoints, patient selection, targets, and timing for the development of successful immune-based treatments ...

Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional ...

Beam Therapeutics' investigational modified cell therapy for treating sickle-cell disease has been granted orphan-drug status by the Food and Drug Administration.

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles ...

Jade Biosciences, Inc. announced that new preclinical data on its investigational anti-APRIL monoclonal antibody, JADE101, will be presented at the 62nd European Renal Association Congress in ...